{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T16:28:19Z","timestamp":1747153699848,"version":"3.40.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s10067-020-05443-3","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T06:02:47Z","timestamp":1602741767000},"page":"2027-2035","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["QuantiFERON\u00ae-TB Gold In-Tube test can be used for screening latent tuberculosis before biological treatment in a Bacille Calmette-Gu\u00e9rin (BCG)-vaccinated country: the HUR-BIO single-center real-life results"],"prefix":"10.1007","volume":"40","author":[{"given":"Emrah","family":"Seyhoglu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0440-2026","authenticated-orcid":false,"given":"O\u011fuz Abdullah","family":"Uyaro\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulsamet","family":"Erden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Levent","family":"Kilic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omer","family":"Karadag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Akdogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sule Apras","family":"Bilgen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ihsan","family":"Ertenli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sedat","family":"Kiraz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umut","family":"Kalyoncu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"issue":"8","key":"5443_CR1","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1002\/art.11137","volume":"48","author":"JJ Gomez-Reino","year":"2003","unstructured":"Gomez-Reino JJ, Carmona L, Valverde VR et al (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48(8):2122\u20132127. https:\/\/doi.org\/10.1002\/art.11137","journal-title":"Arthritis Rheum"},{"issue":"6","key":"5443_CR2","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/j.1469-0691.2011.03555.x","volume":"17","author":"CM Denkinger","year":"2100","unstructured":"Denkinger CM, Dheda K, Pai M (2100) Guidelines on interferon-gamma release assays for tuberculosis infection: concordance, discordance or confusion? Clin Microbiol Infect 17(6):806\u2013814. https:\/\/doi.org\/10.1111\/j.1469-0691.2011.03555.x","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"5443_CR3","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/acr.21641","volume":"64","author":"JA Singh","year":"2012","unstructured":"Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O\u2019Dell J, Winthrop KL, Beukelman T, Bridges SL Jr, Chatham WW, Paulus HE, Suarez-almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64(5):625\u2013639. https:\/\/doi.org\/10.1002\/acr.21641","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"5443_CR4","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1128\/CVI.05299-11","volume":"18","author":"D Vassilopoulos","year":"2011","unstructured":"Vassilopoulos D, Tsikrika S, Hatzara C, Podia V, Kandili A, Stamoulis N, Hadziyannis E (2011) Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy. Clin Vaccine Immunol 18(12):2102\u20132108. https:\/\/doi.org\/10.1128\/CVI.05299-11","journal-title":"Clin Vaccine Immunol"},{"issue":"5","key":"5443_CR5","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/art.22768","volume":"57","author":"JJ Gomez-Reino","year":"2007","unstructured":"Gomez-Reino JJ, Carmona L, Angel Descalzo M et al (2007) Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 57(5):756\u2013761. https:\/\/doi.org\/10.1002\/art.22768","journal-title":"Arthritis Rheum"},{"issue":"11","key":"5443_CR6","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1136\/annrheumdis-2011-200408","volume":"71","author":"X Mariette","year":"2012","unstructured":"Mariette X, Baron G, Tubach F, Liot\u00e9 F, Combe B, Miceli-Richard C, Flipo RM, Goupille P, Allez M, Salmon D, Emilie D, Carcelain G, Ravaud P (2012) Influence of replacing tuberculin skin test with ex vivo interferon gamma release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy. Ann Rheum Dis 71(11):1783\u20131790. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200408","journal-title":"Ann Rheum Dis"},{"key":"5443_CR7","volume-title":"AB0350 rituximab seems outstanding biological option in late onset rheumatoid arthritis: Hur-Bio real life results: BMJ","author":"L Kilic","year":"2016","unstructured":"Kilic L, Erden A, Sari A et al (2016) AB0350 rituximab seems outstanding biological option in late onset rheumatoid arthritis: Hur-Bio real life results: BMJ. Publishing Group Ltd, London"},{"issue":"13","key":"5443_CR8","doi-asserted-by":"publisher","first-page":"e9930","DOI":"10.1097\/md.0000000000009930","volume":"97","author":"B Armagan","year":"2018","unstructured":"Armagan B, Sari A, Erden A et al (2018) Starting of biological disease modifying antirheumatic drugs may be postponed in rheumatoid arthritis patients with multimorbidity: single center real life results. Medicine 97(13):e9930. https:\/\/doi.org\/10.1097\/md.0000000000009930 [published Online First: 2018\/03\/30]","journal-title":"Medicine"},{"key":"5443_CR9","unstructured":"QuantiFERON\u00ae-TB Gold (QFT\u00ae) ELISA Package Insert. http:\/\/www.quantiferon.com\/wp-content\/uploads\/2017\/04\/English_QFT_ELISA_R04_082016.pdf. Accessed August 2016"},{"key":"5443_CR10","unstructured":"TC Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 Halk Sa\u011fl\u0131\u011f\u0131 Genel M\u00fcd\u00fcrl\u00fc\u011f\u00fc. T\u00fcberk\u00fcloz Tan\u0131 Rehberi (TC Ministry of Health Tuberculosis Diagnosis Guide), 2. Bask\u0131. (2019). Art\u01316 Medya Tan\u0131t\u0131m Matbaa Ltd. \u015eti. https:\/\/hsgm.saglik.gov.tr\/depo\/birimler\/tuberkuloz_db\/haberler\/Tuberkuloz_Tani_Ve_Tedavi_Rehberi_\/Tuberkuloz_Tani_ve_Tedavi_Rehberi.pdf. Ankara. Accessed May 2019"},{"key":"5443_CR11","unstructured":"TC Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 Anti-TNF Kullanan Hastalarda T\u00fcberk\u00fcloz Rehberi (TC Ministry of Health Tuberculosis Guide in Patients Using Anti-TNF) (2016). http:\/\/www.romatoloji.org\/Dokumanlar\/Site\/ATKHTR.pdf. Ankara 2016"},{"issue":"7","key":"5443_CR12","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1002\/art.24632","volume":"60","author":"F Tubach","year":"2009","unstructured":"Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Br\u00e9ban M, Pallot-Prades B, Pouplin S, Sacchi A, Chichemanian RM, Bretagne S, Emilie D, Lemann M, Lorthololary O, Mariette X, Research Axed on Tolerance of Biotherapies Group (2009) Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum 60(7):1884\u20131894. https:\/\/doi.org\/10.1002\/art.24632","journal-title":"Arthritis Rheum"},{"issue":"7","key":"5443_CR13","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1002\/art.34382","volume":"64","author":"EC Hsia","year":"2012","unstructured":"Hsia EC, Schluger N, Cush JJ, Chaisson RE, Matteson EL, Xu S, Beutler A, Doyle MK, Hsu B, Rahman MU (2012) Interferon-gamma release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Arthritis Rheum 64(7):2068\u20132077. https:\/\/doi.org\/10.1002\/art.34382","journal-title":"Arthritis Rheum"},{"issue":"9","key":"5443_CR14","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.3899\/jrheum.081292","volume":"36","author":"B Soborg","year":"2009","unstructured":"Soborg B, Ruhwald M, Hetland ML et al (2009) Comparison of screening procedures for Mycobacterium tuberculosis infection among patients with inflammatory diseases. J Rheumatol 36(9):1876\u20131884. https:\/\/doi.org\/10.3899\/jrheum.081292","journal-title":"J Rheumatol"},{"issue":"1","key":"5443_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/ard.2008.101857","volume":"69","author":"J Martin","year":"2010","unstructured":"Martin J, Walsh C, Gibbs A, McDonnell T, Fearon U, Keane J, Codd MB, Dodd J, Veale D, FitzGerald O, Bresnihan B (2010) Comparison of interferon {gamma} release assays and conventional screening tests before tumour necrosis factor {alpha} blockade in patients with inflammatory arthritis. Ann Rheum Dis 69(1):181\u2013185. https:\/\/doi.org\/10.1136\/ard.2008.101857","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"5443_CR16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/BOR.0b013e3283474d62","volume":"23","author":"R Smith","year":"2011","unstructured":"Smith R, Cattamanchi A, Steingart KR, Denkinger C, Dheda K, Winthrop KL, Pai M (2011) Interferon-gamma release assays for diagnosis of latent tuberculosis infection: evidence in immune-mediated inflammatory disorders. Curr Opin Rheumatol 23(4):377\u2013384. https:\/\/doi.org\/10.1097\/BOR.0b013e3283474d62","journal-title":"Curr Opin Rheumatol"},{"key":"5443_CR17","unstructured":"TC Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 (2015) T\u00fcrkiye\u2019de Verem Sava\u015f\u0131 Raporu (TC Ministry of Health 2015 Tuberculosis Control Report in Turkey), Yay\u0131n No: 1059 (2016). Ankara. https:\/\/hsgm.saglik.gov.tr\/depo\/birimler\/tuberkuloz_db\/dosya\/raporlar\/Turkiyede_Verem_Savasi_2015_Raporu.pdf?type=file. Accessed 25 March 2017"},{"key":"5443_CR18","unstructured":"WHO (2014) World Health Organization Global tuberculosis report. Geneva. Accessed 25 March 2017."},{"issue":"3","key":"5443_CR19","doi-asserted-by":"publisher","first-page":"e0119260","DOI":"10.1371\/journal.pone.0119260","volume":"10","author":"H Lee","year":"2015","unstructured":"Lee H, Park HY, Jeon K, Jeong BH, Hwang JW, Lee J, Cha HS, Koh EM, Kang ES, Koh WJ (2015) QuantiFERON-TB Gold In-Tube assay for screening arthritis patients for latent tuberculosis infection before starting anti-tumor necrosis factor treatment. PLoS One 10(3):e0119260. https:\/\/doi.org\/10.1371\/journal.pone.0119260","journal-title":"PLoS One"},{"issue":"10","key":"5443_CR20","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/S1473-3099(18)30355-4","volume":"18","author":"I Abubakar","year":"2018","unstructured":"Abubakar I, Drobniewski F, Southern J, Sitch AJ, Jackson C, Lipman M, Deeks JJ, Griffiths C, Bothamley G, Lynn W, Burgess H, Mann B, Imran A, Sridhar S, Tsou CY, Nikolayevskyy V, Rees-Roberts M, Whitworth H, Kon OM, Haldar P, Kunst H, Anderson S, Hayward A, Watson JM, Milburn H, Lalvani A, Adeboyeku D, Bari N, Barker J, Booth H, Chua F, Creer D, Darmalingam M, Davidson RN, Dedicoat M, Dunleavy A, Figueroa J, Haseldean M, Johnson N, Losewicz S, Lord J, Moore-Gillon J, Packe G, Pareek M, Tiberi S, Pozniak A, Sanderson F (2018) Prognostic value of interferon-\u03b3 release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study. Lancet Infect Dis 18(10):1077\u20131087","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"5443_CR21","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.lpm.2017.01.015","volume":"46","author":"A Matteelli","year":"2017","unstructured":"Matteelli A, Sulis G, Capone S, D\u2019Ambrosio L, Migliori GB, Getahun H (2017) Tuberculosis elimination and the challenge of latent tuberculosis. Presse Med 46(2):e13\u2013e21. https:\/\/doi.org\/10.1016\/j.lpm.2017.01.015","journal-title":"Presse Med"},{"issue":"1","key":"5443_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1128\/CMR.00034-13","volume":"27","author":"M Pai","year":"2014","unstructured":"Pai M, Denkinger CM, Kik SV, Rangaka MX, Zwerling A, Oxlade O, Metcalfe JZ, Cattamanchi A, Dowdy DW, Dheda K, Banaei N (2014) Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev 27(1):3\u201320. https:\/\/doi.org\/10.1128\/CMR.00034-13","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"5443_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.7326\/0003-4819-149-3-200808050-00241","volume":"149","author":"M Pai","year":"2008","unstructured":"Pai M, Zwerling A, Menzies D (2008) Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 149(3):177\u2013184","journal-title":"Ann Intern Med"},{"issue":"11","key":"5443_CR24","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s00296-009-1170-6","volume":"30","author":"T Cagatay","year":"2010","unstructured":"Cagatay T, Aydin M, Sunmez S et al (2010) Follow-up results of 702 patients receiving tumor necrosis factor-alpha antagonists and evaluation of risk of tuberculosis. Rheumatol Int 30(11):1459\u20131463. https:\/\/doi.org\/10.1007\/s00296-009-1170-6","journal-title":"Rheumatol Int"},{"issue":"8","key":"5443_CR25","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","volume":"174","author":"JJ Saukkonen","year":"2006","unstructured":"Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR, ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee (2006) An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 174(8):935\u2013952. https:\/\/doi.org\/10.1164\/rccm.200510-1666ST","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"5443_CR26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jbspin.2009.10.012","volume":"77","author":"MG Bray","year":"2010","unstructured":"Bray MG, Poulain C, Dougados M, Gossec L (2010) Frequency and tolerance of antituberculosis treatment according to national guidelines for prevention of risk of tuberculosis due to tumor necrosis factor blocker treatment. Joint Bone Spine 77(2):135\u2013141. https:\/\/doi.org\/10.1016\/j.jbspin.2009.10.012","journal-title":"Joint Bone Spine"},{"issue":"8","key":"5443_CR27","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s10067-014-2528-z","volume":"33","author":"J Bourre-Tessier","year":"2014","unstructured":"Bourre-Tessier J, Arino-Torregrosa M, Choquette D (2014) Increased incidence of liver enzymes abnormalities in patients treated with isoniazid in combination with disease modifying and\/or biologic agents. Clin Rheumatol 33(8):1049\u20131053. https:\/\/doi.org\/10.1007\/s10067-014-2528-z","journal-title":"Clin Rheumatol"},{"issue":"9","key":"5443_CR28","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.cgh.2015.02.024","volume":"13","author":"PH Hayashi","year":"2015","unstructured":"Hayashi PH, Fontana RJ, Chalasani NP et al (2015) Under-reporting and poor adherence to monitoring guidelines for severe cases of isoniazid hepatotoxicity. Clin Gastroenterol Hepatol 13(9):1676\u20131682.e1","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"5443_CR29","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1164\/rccm.200303-390OC","volume":"168","author":"PA LoBue","year":"2003","unstructured":"LoBue PA, Moser KS (2003) Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 168(4):443\u2013447","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"5443_CR30","first-page":"224","volume":"59","author":"Control CfD, Prevention","year":"2010","unstructured":"Control CfD, Prevention (2010) Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection-United States, 2004\u20132008. MMWR Morb Mortal Wkly Rep 59(8):224","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7","key":"5443_CR31","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","volume":"148","author":"N Chalasani","year":"2015","unstructured":"Chalasani N, Bonkovsky HL, Fontana R et al (2015) Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterol 148(7):1340\u20131352.e7","journal-title":"Gastroenterol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05443-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-020-05443-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05443-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T04:25:02Z","timestamp":1634271902000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-020-05443-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["5443"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-05443-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2020,10,15]]},"assertion":[{"value":"12 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}